Adynamic bone disease (ABD) under influence of aluminium in chronic renal failure and dialysis (HD, CAPD) - Risk of underestimated subclinical Al-toxicity in cases with decreased threshold for Al-toxicity nowadays;Die adynamische knochenerkrankung (ABD) unter aluminiumeinfluß bei chronischer niereninsuffizienz und dialyse (HD, CAPD): Das risiko der unterschätzten subklinischen aluminiumtoxizität bei herabgesetzter toxizitätsschwelle heute

Nieren- und Hochdruckkrankheiten

Volumn 25, Issue 2, 1996, Pages 50-71

  Humpfner A ^a,b  

^a KLINIKUM BAMBERG   (Germany)

^b NONE   (Germany)

Author keywords

Al induced adynamic bone disease; Clinical appearance of Al accumulation; Epidemiology; Modulating factors of Al toxicity; Pathogenesis of Al osteotoxicity; Prevalence of Al osteopathy and Al ABD; Subclinical Al toxicity

Indexed keywords

ALUMINUM;

BLOOD LEVEL; CHRONIC KIDNEY FAILURE; DRUG INTOXICATION; EARLY DIAGNOSIS; HISTOLOGY; HUMAN; OSTEOMALACIA; PATHOGENESIS; PREVALENCE; RENAL OSTEODYSTROPHY; REVIEW; RISK FACTOR;

EID: 0030010306     PISSN: 03005224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Abreo K., J. Glass: Cellular, biochemical and molecular mechanism of aluminium toxicity. Nephrol. Dial. Transplant. 8 (Suppl. 1), 5-11 (1993).
2. Achenbach II.: Aluminiuminduzierte Osteopathie - Pathogenetische Mechanismen. Zeitschrift für die gesamte Innere Medizin und ihre Grenzgebiete 44, 133-137 (1989).
3. Alfrey A.C.: The aluminium intoxication syndrome. Vortrag beim Symposium Spurenelemente, Münster 1987.
4. Alfrey A.C., G.K. LeGendre, W.D. Kaehny: The dialysis encephalopathy syndrome. Possible aluminium intoxication. N. Engl. J. Med. 294, 184-188 (1976).
5. Altmann P.: Aluminium toxicity in dialysis patients: no evidence for a threshold serum aluminium concentration. Nephrol. Dial. Transplant. 8 (Suppl. 1), 25-34 (1993).
6. Andress D.L., NA. Maloney, J.W. Coburn, D.B. Endress, D.J. Sherrard: Osteomalacia and aplastic bone disease in aluminium related osteodystrophy. J. Clin. Endocrinol. Metab. 65, 11-16 (1987).
7. BerlandJ., M. Charbit, J.F. Henry, M. Toga, J.P. Cano, M. Olmer: Aluminium overload of parathyroid glands in hemodialysed patients with hyperparathyroidism: effect on bone remodelling. Nephrol. Dial. Transplant 3, 417-422 (1988).
8. Chazan J.A., N.L. Lew, E.G. Lowrie: Increased serum aluminium: an independent risk factor for mortality in patients undergoing long-term hemodialysis. Arch. Intern. Med. 151, 319-322 (1991).
9. Chazan J.A., N.P. Libbey, M.R. London, L. Pono, J.G. Abuelo: The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings. Clin. Nephrol. 35, 78-85 (1991).
10. Cohen-Solal M.E., B. Boundailliez, J.L. Sebert, R. Bouillon, A. Fournier: Comparison of intact, medium and carboxy-terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialysis patients. J. Clin. Endocrin. Metab. 73, 516-524 (1991).
11. Cohen-Solal M.E., J.L. Sebert, B. Boudailliez, P.F. Westeel, P.H. Moriniere, A. Marie, M. Garabedian, A. Fournier: Non-aluminic adynamic bone disease in non-dialyzed uremic patients, a new type of osteopathy due to overtreatment. Bone 13, 1-5 (1992).
12. Consensus Conference: Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol. Dial. Transplant 8 (Suppl. 1), 1-4 (1993).
13. Couttenye MM., P.C. D'Haese, V.O. van Hoof, W. Goodmann, M.E. DeBroe: Bone alkaline phosphatase as a marker of renal osteodystrophy, more specifically of the adynamic type. Vortrag beim Workshop Renale Osteopathie und Nierenersatztherapieverfahren unter besonderer Berücksichtigung der Low-turnover-Osteopathie/Osteopenie. Bamberg 1995.
14. DeBroe M.E., P.C. D'Haese, F.L. van de Vyver, L.V. Lamberts: Aluminiuminduzierte Osteopathie bei Patienten mit chronischer Niereninsuffizienz. Nieren- und Hochdruckkrankh. 7, 311-316 (1991).
15. DeBroe M.E., P.C. D'Haese, M.M. Couttenye, G.F. van Landegham, L.V. Lambert: New insights and strategies in the diagnosis and treatment of aluminium overload in dialysis patients. Nephrol. Dial. Transplant. 8 (Suppl. 1), 47-50 (1993).
16. Degenhardt S.: Renale Osteopathie unter CAPD. Vortrag beim Workshop Renale Osteopathie und Nierenersatztherapieverfahren unter besonderer Berücksichtigung der Low-tumover-Osteopathie/Osteopenie. Bamberg 1995.
17. Delling G.: Pathomorphologie renaler Osteopathien. Vortrag beim Workshop Renale Osteopathie und Nierenersatztherapieverfahren unter besonderer Berücksichtigung der Low-turnover-Osteopathie/Osteopenie. Bamberg 1995.
18. Delling G., Th. Dreyer, M. Vogel, M. Hahn: Renale Osteopathie - morphologische Charakteristika und Einfluß von Aluminium auf die Knochenstruktur. In: Aluminium und Niereninsuffizienz, aktuelle Diagnostik und Therapie. Symposium (Ciba-Pharma), Düsseldorf 1988.
19. D'Haese P.C., J.P. Clement, MM. Elseviers, L.V. Lamberts, F.L. van de Vyver, W.J. Visser, M.E. DeBroe: Value of serum aluminium monitoring in dialysis patients: a multicentre study. Nephrol. Dial. Transplant. 5, 45-53 (1990).
20. Drucke T.B.: Adynamic bone disease, anaemia, resistance to erythropoietin and iron-aluminium interaction. Nephrol. Dial. Transplant. 8 (Suppl. 1), 12-16 (1993).
21. Faugere M.C., I.O. Ornala, E. Ritz, H.H. Malluche: Loss of bone resulting from accumulation of aluminium in bone in patients undergoing dialysis. J. Lab. Clin. Med. 107, 481-487 (1986).
22. Felsenfeld A.J., M. Kodriguez, M. Coleman, D. Ross, F. Llach: Desferrioxamine therapy in hemodialysis patients with aluminium associated bone disease. Kidney Int. 35, 1371-1378 (1989).
23. Fournier A., B. Boudailliez, Ph. Moriniere, M.E. Cohen-Solal, A. Marie, J.E. Sebert: Aluminiumunabhängige adynamische Osteopathie bei Urämie. Bedeutung und Prognose. Nieren- und Hochdruckkrankh. 21, 313-318 (1992).
24. Frost H.M.: Osteopenia: the ADFR treatment. In: Frame B., J.T. Potts: Clinical disorders of bone an mineral metabolism. Excerpta Medica, Amsterdam 1983, 372.
25. Hamdy N.A.T., J. Ristelli, L. Risteli, S. Harris, M.N.C. Beneton, C.B. Brown, J.A. Kanis: Serum type I procollagen peptide, a non-invasive index of bone formation in patients on hemodialysis. Nephrol. Dial. Transplant. 9, 511-516 (1994).
26. Hercz G., Y. Pei, C. Greenwood, A. Manuel, C. Saiphoo, W.G. Goodmann, G.V. Segre, S. Fenton, D.J. Sherrard: Aplastic osteodystrophy without aluminium. The role of "suppressed" parathyroid function. Kidney Int. 44, 860-866 (1993).
27. Hernandez D., M.T. Concepcion, V. Lorenzo, M.E. Martinez, A. Rodriguez, E. De Binis, J.M. Gonzalz-Posada, A.J. Felsenfeld, M. Rodriguez, A. Torres: Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol. Dial. Transplant. 9, 517-523 (1994).
28. Herrath von D.: Zur Klinik der renalen Osteopathie. In: Malluche H.H., H.E. Franz: Renale Osteopathie. Symposium, Ulm 1988. Wissenschaftl. Verlagsgesellschaft mbH, Stuttgart 1990, 11-20.
29. Hümpfner A.: Aluminiumintoxikation bei Niereninsuffizienz: Geschichte, Klinik, Therapie und Prävention. Zuckschwerdt-Verlag, München 1989.
30. Hümpfncr A.: Klinik der Aluminium-Osteopathie (frakturierende Osteopathie). Nieren-und Hochdruckkrankh. 20, 328-338 (1991).
31. Hûmpfer A.: Risikofaktoren für die Entwicklung einer Aluminiumüberladung. Checkliste, Ciba Pharma 1991.
32. Hümpfner A., W. Schulz: Differentialdiagnose und Therapie der Dialyse-Enzephalopathie unter Berücksichtigung der zerebralen Vorschädigung und des Aluminiumeinflusses. In: Aluminium und Dialyse. Symposium, Bamberg 1988 (Ciba Pharma).
33. Hümpfner A., S. Hummel, W. Schulz: Diagnostic and therapeutical approaches to aluminium overload in dialysis patients: representative study by questionnaire in West German dialysis units in 1989. Nephrol. Dial. Transplant. 8 (Suppl. 1), 51-54 (1993).
34. Hutchison A.J., R.W. Whithehouse, H.F. Boulton: Characteristics and natural history of adynamic bone in CAPD. J. Am. Nephrol. 3, 673 (1992) (Abstract).
35. Hutchison A.J., R.W. Whithehouse, H.F. Boulton, J.E. Adams, E.B. Mawer, T.J. Freemont, R. Gokal: Correlations of bone histology with parathyroid hormone, vitamin D3 and radiology in end-stage renal disease. Kidney Int. 44, 1071-1077 (1993).
36. Ittel T.H.: Resorption und Toxizität von Aluminium bei Niereninsuffizienz. In: Ittel T.H., H.G. Siebert, H.H. Matthiaß: Aktuelle Aspekte der Osteologie. Springer, Berlin 1992, 139-148.
37. Ittel T.H.: Determinants of gastrointestinal absorption and distribution of aluminium in health and uremia. Nephrol. Dial. Transplant. 8 (Suppl. 1), 17-24 (1993).
38. Ittel T.H.: Aluminiumosteopathie: Diagnostik und Therapie. 18. Nephrologisches Seminar, Heidelberg 1994, 256-261.
39. Ittel T.H., E. Ritz, G. Stein: Diagnostik und Therapie der Aluminium-Intoxikation. Münch. Med. Wschr. 38, 822-824 (1992).
40. Ittel T.H., E. Gruber, A. Heinrich, S. Handt, F. Hofstädter, H.G. Siebert: Effect of fluoride on aluminium induced bone disease in rats with renal failure. Kidney Int. 41, 1340-1348 (1992).
41. Jorgetti V., N.M. Soeiro, V. Menders, R.C. Pereirea, ME. Crivellari, G. Contris, A. Borelli, M.O. Leite, J. Nussenzweig, M. Marcondes: Aluminium-related osteodystrophy and desferrioxamine treatment: role of phosphorus. Nephrol. Dial. Transplant. 9, 668-674 (1994).
42. Kerr D.N.S., M.K. Ward: The history of aluminium related disease. In: Aluminium and other trace elements in renal disease. Balliere Tindall, London 1986.
43. Kerr D.N.S., M.K. Ward, R.S. Arze: Aluminium-induced osteodystrophy: the demise of Newcastle bone disease. Kidney Int. 29 (Suppl. 18), 58-64 (1986).
44. Kurz P., M.C. Monier-Faugere, B. Bognar, E. Werner, P. Roth, J. Vlachojannis, H.H. Malluche: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 46, 855-861 (1994).
45. Llach F., A.J. Felsenfeld, M.D. Coleman, J.J. Keveney, J.A. Pederson, T. Medlock: The natural course of dialysis osteomalacia. Kidney Int. 29 (Suppl. 18), 74-89 (1986).
46. Malluche H.H., M.C. Monier-Faugere: Risk of adynamic bone disease in dialyzed patients. Kidney Int. 42 (Suppl.38), 62-67 (1992).
47. Mazzaferro S., G. Coen, P. Ballanti, S. Costantini, F. Bonnucci: Desferrioxamine test and PTH serum levels are useful not to recongnize but to exclude aluminium-related bone disease. Nephrono 61, 151-157 (1992).
48. Morrisey J., E. Slatapolsky: Effect of aluminium on parathyroid hormone secretion. Kidney Int. 29 (Suppl. 18), 41-44 (1986).
49. Nebecker H.G.: Aluminium and renal osteodystrophy. Ann. Rev. Med. 37, 79 (1986).
50. Nordal K.P., E. Dahl, D. Albrechtsen, J. Halse, T. Leivestad, S. Tretli, A. Flatmark: Aluminium accumulation and immunosuppressive effect in recipients of kidney transplants. Br. Med. J. 297, 1581-1582 (1988).
51. Norris K.C.: Clinical and laboratory features of aluminium-related disease: differences between sporadic and "epidemic" forms of the syndrome. Am. J. Kid. Dis. 6, 342 (1985).
52. O'Brien A.A.J., D.P. Moore, J.A.B. Keogk: Aluminium osteomalacia in chronic renal failure patients neither on dialysis nor taking aluminium containing phosphate binders. Ir. J. Med. Sci. 159, 74-76 (1990).
53. Ott S.M.: Aluminiumlokalisation im Knochen. Nieren- und Hochdruckkrankh. 20, 317-320 (1991).
54. Parkinson I.S., M.K. Ward, D.N.S. Kerr: Dialysis encephalopathy, bone disease and anaemia: the aluminium intoxication syndrome during regular hemodialyis. J. Clin. Path. 34, 1285-1294 (1981).
55. Pei Y., G. Hercz, C. Greenwood, DJ. Sherrard, G. Segre, A. Manual, C. Saiphoo, S. Fenton: Non-invasive prediction of aluminium bone disease in hemo-and peritoneal dialysis patients. Kidney Int. 41, 1374-1382 (1992).
56. Piraino B.,T. Chen, I. Cooperstein, C. Segre, S. Puschelt: Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin. Nephrol. 30, 57-62 (1988).
57. Posen G.A., D. Gray, J.Y. Siddiqui: Bone disease in patients on regular hemodialysis: evidence for a water factor. QJ. Med. 41, 534-535 (1972).
58. Rodriguez M., V. Lorenzo, A.J. Felsenfeld, F. Llach: Effect of parathyroidectomy on aluminium toxicity and azotemic bone disease in the rat. J. Bone Miner. Res. 5, 379-386 (1990).
59. Rodriguez-Perez J.C., C. Plaza, A. Torres, N. Vega, A. Anabitarta, A. Fernandez, V. Lorenzo, L. Hortal, L. Palop: Low turnover bone disease is the more common form of bone disease in CAPD patients. Adv. Perit. Dial. 8, 376-380 (1992).
60. RosenlöfK., F. Fyhrquist, R. Teukunen: Erythropoietin, aluminium and anaemia in patients on hemodialysis. Lancet 335, 247-249 (1990).
61. Schulz W.: Oral therapy of aluminium hydroxide in long-term dialysis patients with special regard to the effect of renal osteodystrophy. International workshop on the role of biological monitoring in the prevention of aluminium toxicity in man. Luxemburg 1982.
62. Schulz W., G. Delling: Osteopenie: ein Problem der Langzeitdialyse. Fortschritte der Medizin 6, 222-227 (1982).
63. Sherrard D.J., S. Ott, N. Maloney, D. Andress, J. Coburn: Uremic osteodystrophy, classification, cause and treatment. In: Frame B., J.T. Potts: Clinical disorders Of bone and mineral metabolism. Excerpta Medica, Amsterdam 1983, 254-259.
64. Sherrard D.J., G. Hercz, Y. Pei, NA. Maloney, C. Greenwood, A. Manuel, C. Saiphoo, S.S. Fenton, G.V. Segre: The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int. 43, 436-442 (1993).
65. Slanina P., W. Frech, L.G. Ekström, L. Lööf, S. Slorad, A. Cedergren: Gastrointestinal absorption of aluminium containing drugs: influence of dietary factors. Trace Elements in Medicine 2, 3128-3129 (1985).
66. Sprague S.M., H.L. Corwin, C.M. Tanner, R.S. Wilson, B.J. Green, C.G. Goetz: Relationship of aluminium to neurocognitive dysfunction in chronic dialysis patients. Arch. Intern. Med. 148, 2169-2172 (1988).
67. Thomas W.C.: Trace meteal-citric acid complexes as inhibitors of calcification and crystal formations. Proc. Exp. Biol. Med. 170, 321-327 (1982).
68. Zhu J.M., W. Huffer, A.C. Alfrey: Effect of aluminium on bone matrix inductive properties. Kidney Int. 38, 1141-1145 (1990).